Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Molycorp Posts $26.6 Mln Profit In Q4

Molycorp Inc (MCP: Quote) reported fourth quarter of 2011 net income attributable to common stockholders was $26.6 million, or $0.26 per share. Adjusted EPS of $0.41 per share takes into account certain non-cash and other out-of-ordinary operational and business expansion items as compared to U.S. GAAP earnings per share.

Quarterly net revenues were $132.9 million, significantly higher than $21.7 million in the fourth quarter of 2010.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.41 per share on revenues of $134.95 million for the quarter. Analysts' estimates typically exclude special items.

The Company re-affirmed its annual production of REO equivalent products to be in a range of 8,000 metric tons to 10,000 metric tons for the full year 2012.

Click here to receive FREE breaking news email alerts for Molycorp, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.